Infectologia
AstraZeneca encabeça o alerta contra a corrida por doses de reforço – “Dar a terceira dose aos mais vulneráveis, que talvez não tenham feito uma resposta imunológica completa com as duas primeiras doses, é ‘sensato’, mas qualquer decisão sobre dar a terceira dose ‘para grande parcela da população’ e ampliar a proteção obtida pelas duas primeiras doses deve ser baseada em dados clínicos.”
12 Set, 2021 | 20:57hAstraZeneca bosses warn against rush for boosters – BBC
Comentário no Twitter (fio – clique para saber mais)
"Moving too quickly to boost across the entire adult population will deprive us of these insights, leaving this important decision to rest on limited data," Mr Soriot and Sir Mene write.https://t.co/xTAk7yyu5G
— The Sharing Scientist (@ScienceShared) September 8, 2021
[Preprint] Estudo randomizado | Reforço vacinal com vacina heteróloga vs. homóloga em pacientes imunossuprimidos sem soroconversão de anticorpo contra SARS-CoV-2 após vacinação primária com vacina de mRNA.
12 Set, 2021 | 20:55h
Comentário no Twitter (fio – clique para saber mais)
Results of 60-person randomized trial of 3rd shot of mRNA or AZ vax in people on rituximab who didn't seroconvert after BNT-Pfizer (most) or Moderna vax. Found dose 3 reduced those with no humoral or cellular response from 31% to 6% …1/2 https://t.co/HIjeDaFy7w Preprint #IC
— Hilda Bastian, PhD (@hildabast) September 8, 2021
Perspectiva | O plano para acabar de vez com todos os vírus respiratórios – “Os benefícios da ventilação vão além do coronavírus. E se, além disso, também não tivéssemos mais gripes ou resfriados?”
12 Set, 2021 | 20:53hThe Plan to Stop Every Respiratory Virus at Once – The Atlantic
Conteúdos relacionados:
Recommendations for ventilation of indoor spaces to reduce COVID-19 transmission.
We studied how to reduce airborne COVID spread in hospitals. Here’s what we learnt.
WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19
CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk
Equilíbrio entre incentivos e incentivos contrários à vacinação numa pandemia.
12 Set, 2021 | 20:51hBalancing incentives and disincentives for vaccination in a pandemic – Nature Medicine
Conteúdo relacionado: Opinion | COVID vaccines: we need to find out which incentives actually work – the author argues that policies to promote vaccine uptake should be tested in randomized clinical trials.
Amplo estudo observacional sugere que uma dieta rica em vegetais pode reduzir o risco de desenvolver COVID-19 grave.
12 Set, 2021 | 20:50hEating a plant rich diet reduces risk of developing COVID-19 – King’s College London
Estudo original: Diet quality and risk and severity of COVID-19: a prospective cohort study – Gut
Estudo randomizado | Um curso de 7 dias de antibióticos para o tratamento de infecções da corrente sanguínea por enterobactérias não foi inferior a um curso de 14 dias.
12 Set, 2021 | 20:14h
Comentário no Twitter
SHORTEN RCT 🔥🔥🔥@CMIJournal
Seven versus 14-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales
7-day course of antibiotics as the preferential treatment for eBSI, as long as the source is properly controlled https://t.co/pyaOMl52us pic.twitter.com/wK1sgeMe36— Antibiotic Steward 🆔🇵🇸 Bassam Ghanem (@ABsteward) September 8, 2021
Revisão Cochrane | As evidências são insuficientes para se chegar a conclusões significativas sobre se os anticorpos monoclonais específicos para o SARS-CoV-2 são eficazes no tratamento da COVID-19.
8 Set, 2021 | 15:25hRevisão original: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library
Disseminação da variante Delta do SARS-CoV-2 é causada pela combinação de escape imunológico e infectividade aumentada.
8 Set, 2021 | 15:23hArtigo original: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion – Nature
Estudo mostra alta efetividade da vacina de mRNA da Pfizer contra a COVID-19 na gestação.
8 Set, 2021 | 15:22hEffectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy – Nature Medicine
Comentários no Twitter
NEW: Estimated vaccine effectiveness in #pregnancy from 7 through to 56 d after second dose was 96% (95% CI; 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms & 89% (43–100%) for #COVID19-related hospitalization. https://t.co/bm950wUWGL
— All Source Pregnancy (@PregnancyAll) September 7, 2021
The Pfizer-BioNTech mRNA COVID-19 vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population, according to a @NatureMedicine paper. https://t.co/oz5zn7zNdq pic.twitter.com/9IP5ocxzXs
— Nature Portfolio (@NaturePortfolio) September 7, 2021
Crianças e COVID: por que sistemas imunológicos jovens ainda estão no topo.
8 Set, 2021 | 15:20hKids and COVID: why young immune systems are still on top – Nature